Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA snubs Novartis bid...

    FDA snubs Novartis bid to repurpose inflammation drug canakinumab for heart attacks

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-21T10:01:18+05:30  |  Updated On 21 Oct 2018 10:01 AM IST
    FDA snubs Novartis bid to repurpose inflammation drug canakinumab for heart attacks
    In trials for heart disease, Novartis discovered a potential benefit in lung cancer patients for the drug, prompting the company to start cancer trials and to promote the medicine's potential for smokers who also suffered from heart disease.

    ZURICH: The U.S. Food and Drug Administration has rejected Novartis's bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, the Swiss drugmaker said on Thursday.

    The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those cardiovascular patients who in tests had quickly responded to treatment, as levels of a protein in their blood associated with inflammation and heart disease quickly plunged.

    Canakinumab made headlines in 2017, when data from a six-year study of about 10,000 patients proved that fighting inflammation with the drug - not merely lowering cholesterol - helped heart attack victims avoid future attacks or death.

    But while scientists lauded the results of Novartis's Cantos study as a revelation, the benefit of the medicine was downplayed by some cardiovascular experts who concluded it was insufficient to justify expanding existing approvals to routine use in cardiac patients.

    "Based on the correspondence, the Cantos data would not support labeling for the use of canakinumab as a targeted therapy for those patients with cardiovascular disease who achieved a reduction of hsCRP below the 2 mg/L target," Novartis said in a statement.

    A big challenge Novartis always faced with canakinumab, also known as Ilaris, is it now costs some $200,000 annually for treating rare inflammatory diseases like Mediterranean fever.

    Cardiology drugs costs just a fraction of that, so Novartis would have had to win favorable labelling from regulators.

    "We're now evaluating the full details of what's in the complete response letter, and trying to determine what is the best course of action," a Novartis spokesman told Reuters. "It's not clear what the next steps are."

    The cardio market is huge, with a quarter of the 1.3 million people who suffer heart attacks in the United States and Europe annually likely to have another attack within five years.

    But in its current uses, Ilaris is comparatively small, racking up sales of $402 million last year.

    In trials for heart disease, Novartis discovered a potential benefit in lung cancer patients for the drug, prompting the company to start cancer trials and to promote the medicine's potential for smokers who also suffered from heart disease.

    In spite of the FDA snub in heart disease, Novartis said Phase 3 canakinumab trials in non-small cell lung cancer would continue and are due to be completed in 2022.

    Read Also: Novartis launches heart drug counter-offensive

    canakinumabcardiac patientsCardiology drugsCardiovasculardrug for heart attacksFDA letterFDA snubheart attackheart diseaseIlarisNovartisSwiss drugmakerUS Food and Drug AdministrationUSFDAZURICH
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok